MedTrace Logo

Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells

NCT04382547 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2021-08-23

No results posted yet for this study

Summary

Treatment of patients with Covid-19 associated pneumonia using intravenous injection of allogenic pooled olfactory mucosa-derived mesenchymal stem cells

Conditions

Interventions

BIOLOGICAL

Allogenic pooled olfactory mucosa-derived mesenchymal stem cells

Allogenic pooled olfactory mucosa-derived mesenchymal stem cells

OTHER

Standard treatment according to the Clinical protocols

Standard treatment according to the Clinical protocols

Sponsors & Collaborators

  • Belarusian State Medical University

    collaborator OTHER

  • Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

    lead OTHER_GOV

Principal Investigators

  • Andrei Y Hancharou, Dr. · Director, the Institute of Biophysics and Cell Engineering of NAS of Belarus

  • Eduard A Dotsenko, Dr., prof. · Head of the chair, Belarusian State Medical University

  • Natalia G Antonevich, Dr. · Head of the Lab of Institute of Biophysics and Cell Engineering of NAS

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-11
Primary Completion
2021-06-30
Completion
2021-06-30

Countries

  • Belarus

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04382547 on ClinicalTrials.gov